Over the past few years a trend toward slow development has been observed on the part of producers of active pharmaceutical ingredients (APIs) in Russia. Domestic manufacturers of substances have not only resumed production but also broadened the range of manufactured substances.
However, API production in Russia is still not a particularly substantial component of the business of pharmaceutical companies. It has been estimated that only 15% of APIs consumed in Russia are produced on the domestic market, according to the latest report from Polish market research group PMR, titled Pharmaceutical contract manufacturing and API sourcing in Russia, Ukraine and the Baltic States 201.
China and India constitute stiff competition for Russian API companies
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze